Antibody discovery remains one of the most challenging aspects in antibody therapeutic development. Some of the biggest technology gaps reported in antibody discovery include diversity of antibody repertoires, functional screening, and lack of suitable in vitro models.
Common antibody discovery technologies, such as B cell sequencing, phage display, and hybridoma generation can yield successful antibody candidates. However, there are several circumstances in which these discovery technologies may be unfeasible or yield unsuccessful results. A proteomics approach to antibody discovery offers a promising strategy to overcome the roadblocks associated with other discovery technologies. By utilizing REpAb polyclonal sequencing, antibody discovery with mass spectrometry enables the exploration of the natural immune repertoire with unparalleled antibody diversity. Additionally, polyclonal antibody sequencing creates a pathway for the discovery of human antibodies by leveraging the unique and diverse human antibody repertoire.
Under what circumstances can a proteomics and mass spectrometry-based antibody discovery approach provide a solution for previously failed discovery attempts?
In this webinar, we delve into case studies where previous antibody discovery campaigns faced challenges in generating successful lead candidates until the implementation of REpAb polyclonal antibody sequencing. Moreover, we analyze various case studies to examine the conditions under which REpAb polyclonal antibody sequencing proves to be the most suitable and feasible platform for antibody discovery.